../Articles/Point.pdfThis article discusses the Doha Ministerial meet.Article11-Dec-2001PharmaBiz../Articles/An ode to the Budget.pdfThis article, in the form of an ode, requests the FM to do away with regulatory pricing in the Pharma industry.Article29-Jan-2002PharmaBiz../Articles/Some Myths and Few Facts.pdfThis article states some myths and a few facts regarding the Indian Pharmaceutical Industry.Article29-May-2002Pharmabizhttp://www.gnaipr.com/Articles/A problem of mindset.pdfThis article details the changes in mindset that have to be made in the Indian Pharma industry to meet the strong global demand. Article23-July-2002PharmaBizhttp://www.gnaipr.com/Articles/Pharma Technology Upgradation.pdfThis article states the need for technology upgradation in the Indian Pharma sector.30-Jan-2003http://www.gnaipr.com/Articles/Hathi mere sathi.pdfThis article starting with an anecdote, takes a brief look at the Hathi Commission Report.Article17-May-2003Pharma Pulsehttp://www.gnaipr.com/Articles/Patent Rules 2003.pdfThis article is a critical commentary on the changes in the Patent Law.Article23-May-2003http://www.gnaipr.com/Articles/Indian Patent Law and Pharma Industry.pdfThis article discusses the Indian Patent Law w.r.t. the Pharma Industry. Article29-May-2003PharmaBizhttp://www.gnaipr.com/Articles/Balancing benefits and downsides of Intellectual Property.pdfThis article discusses the balancing act to be performed by various countries with regards to IP.Article18-Jun-2003PharmaBizhttp://www.gnaipr.com/Articles/Patent Rules.pdfThis article discusses the changes brought about by the Patent (Amendment) Act, 2002.Article9-July-2003PharmaBizhttp://www.gnaipr.com/Articles/Countdown 2005.pdfThis article discusses the problems faced on the road from Doha to Cancun.Article3-Sep-2003PharmaBizhttp://www.gnaipr.com/Articles/IP in India.pdfThis article discusses the limited options facing India regarding IP.Article25-Dec-2003PharmaBizhttp://www.gnaipr.com/Tutorials/articles.phpThis article states that the Drug Controller should be a person from the Industry and the advantages of the same.Article9-Feb-2004Pharma Pulsehttp://www.gnaipr.com/Articles/Emergency Encounter and other Reminiscences.pdfThis article takes a look at a few meetings Dr. Gopakumar Nair attended in Delhi, during the Emergency.Article31-May-2004Pharma Pulsehttp://www.gnaipr.com/Tutorials/articles.phpThis article takes a look at the problem of "perennial patenting" with regards to micro-organisms. Article31-May-2004PharmaBizhttp://www.gnaipr.com/Articles/The discovery of india.pdfThis article cries out for a re-discovery of India for its technological treasures.Article28-Jun-2004Pharma Pulsehttp://www.gnaipr.com/Articles/Product patents and transition status.pdfThis article discusses the 3rd Amendment to The Patent Act, 1970.Article23-Dec-2004PharmaBizhttp://www.gnaipr.com/Articles/Pharmapulse-Ordinance 2004(Patent Tsunami or Parting Gift).pdfThis article mentions a few salient features of the 2004 Ordinance to the Patent Act, 1970.Article29-Dec-2004Pharma Pulsehttp://www.gnaipr.com/Articles/Option in Transition - Patent Ordinance - 2004.pdfThis article states the new features of the new ordinance issued by the Government of India.Article29-Dec-2004PharmaBizhttp://www.gnaipr.com/Articles/Additional Features of New Patent Ordinance.pdfThis article draws attention to certain aspects of the new patent amendment that needs closer attention.Article15-Jan-2005PharmaBizhttp://www.gnaipr.com/Articles/Harmonized patent law installed at wipo.pdfThis article gives an overview of the problems faced by SPLT (Substantive Patent Law Treaty) at the June meeting of the SCP (Standing Committee on the Law of Patents).Article23-Jun-2005PharmaBizhttp://www.gnaipr.com/Articles/Evergreening.pdfThis article takes a look at the anti-evergreening steps taken by the Indian Parliament and a case study regarding a recent US judgment concerned with evergreening.Article22-Oct-2005http://www.gnaipr.com/Articles/IP Protection.pdfThis article gives the scenario of IP protection in India, after 2004.Article1-Dec-2005PharmaBizhttp://www.gnaipr.com/Articles/Gleevec Order.pdfThe decision of the Indian Patent Office (IPO) regarding the opposition filed by M/s Cipla Ltd to the patent application no. 1602/MAS/1998 filed by M/s Novartis AG for Gleevec (Imatinib Mesylate). Articlehttp://www.gnaipr.com/Articles/TRIPs & Patents.pdfThis is the first draft of the article which appeared in Modern Pharmaceuticals, August-September 2006 and describes the impact of TRIPS on the Indian Pharmaceutical industry.ArticleAug-2006Modern Pharmaceuticalshttp://www.gnaipr.com/Articles/data exclusivity.pdfThis article gives the significance of data exclusivity for the Indian pharma industry and a practical model for implementing the same.Article28-Sep-2006PharmaBizhttp://www.gnaipr.com/Articles/Towards greater IPR protection.pdfThis article takes a look at the current IPR scenario in the Middle East countries, giving UAE as a specific example.Article19-Oct-2006PharmaBizhttp://www.gnaipr.com/Articles/People assets.pdfIn this article, Dr. Gopakumar Nair opines that a road block to the Indian pharma success story could be diminishing human resources.Article1-Nov-2006Express Pharmahttp://www.gnaipr.com/Articles/Incremental innovations in drug research.pdfThis article takes a look at the rising importance of "Incremental Innovations" for pharma companies and also takes a look at the Indian scenario for the same.Article30-Nov-2006PharmaBizhttp://www.gnaipr.com/Articles/Pharmexcil1.pdfIn this article, Dr. Nair takes an in-depth look at the Indian Patent Act and its impact on the Indian Pharma Industry.Article2006Pharmexcilhttp://www.gnaipr.com/Articles/DPRP.pdfInvitation from the Department of Science and Technology for Research Proposals from Academic Institutions/National Laboratories and Industries in Drugs and Pharma Sector under the Drugs and Pharmaceutical Research Programme (DPRP). Articlehttp://www.gnaipr.com/Articles/Mashelkar Committee Report.pdf Articlehttp://www.gnaipr.com/Articles/timetobridgethegulf.pdfIn this article, Dr. Nair takes a look at the potential for growth for the Indian Pharma sector in the Gulf countries.Article25-Jan-2007PharmaBizhttp://www.gnaipr.com/Articles/modernpharmafeb.pdfIn this article, Dr. Nair takes a look at the Indian Pharma Industry and the future trends in the industry.ArticleFeb-Mar-2007Modern Pharmaceuticalshttp://www.gnaipr.com/Articles/scan00033.jpgThe controversial patent litigation over Glivec has come to almost to an end on last Monday with the Madras High Court rejecting Novartis' petition challenging Article9-Aug-2007CHRONICLE PHARMABIZhttp://www.uspto.gov/web/offices/com/sol/notices/72fr46716.pdfUSPTO moving forward to improve patent quality -Federal Register publishes new draft rules will become effective 1st November 2007.For details go toArticle20-Aug-2007USPTOhttp://www.expresspharmaonline.com/20070930/management01.shtmlPharma companies employ various strategies while drafting patent claims.Article22-Sep-2007Express Pharmahttp://www.pharmabiz.com/article/detnews.asp?articleid=40917&SectionID=50India's entry into the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) compliant product patent regime has stirred hornet's nest in the global IP scenario.Article27-Sep-2007PharmaBizhttp://www.uspto.gov/web/offices/com/sol/notices/72fr57526.pdf Articlehttp://www.uspto.gov/web/offices/com/speeches/07-43.htmThe Department of Commerce's United States Patent and Trademark Office (USPTO) has published Examination Guidelines (Guidelines) to help USPTO examiners make appropriate decisions regarding the obviousness of claimed inventions in light of the Supreme Court's decision in KSR International Co. v. Teleflex Inc., 550 U.S., 82 USPQ2d 1385 (2007) (KSR). Article10-Oct-2007USPTOhttp://www.pharmabiz.com/article/detnews.asp?articleid=41377&SectionID=Ranbaxy Laboratories Limited (RLL) has announced that the Federal Patent Court of Germany located in Munich, handed down a favourable decision for Ranbaxy in its case against (Pfizer) Warner-Lambert's European Patent 409 281 (281)Our Bureau, MumbaiArticle31-Oct-2007PharmaBizhttp://www.uspto.gov/web/offices/com/sol/notices/72fr46716.pdfRecent USPTO Announcement of postponing the implementation of proposed revision in the rules of practice in USPTO.The report is reproduced .Article5-Nov-2007USPTOhttp://www.pharmabiz.com/article/detnews.asp?articleid=42056&sectionid=50The emergence of Pre-grant opposition is a newly emerging hot topic of discussion on the international scenario too. Ashwini Sandu & Raju Kumar,ChronicleArticle13-Dec-2007PharmaBizhttp://www.pharmabiz.com/article/detnews.asp?articleid=42055&sectionid=50The emergence of intellectual property (IP) through WTO & TRIPs to the forefront of international trade had taken India by surprise in the early 90's.Dr Gopakumar G. Nair,ChronicleArticle13-Dec-2007PharmaBizhttp%3A%2F%2Fspicyipindia.blogspot.com%2F2008%2F05%2Fwhy-is-dgci-trying-to-implement-patent.html%3FshowComment%3D1210323240000The Drug Controller General of India - Dr. Surinder Singh - has made a public statement that he intends to link up regulatory approval for drugs to the patenting system i.e. he has gone on to record to state that the DCGI will not grant regulatory approval for generic drugs if in case the innovator drug still has a valid patent covering it.Prashant ReddyNews09-May-2008Spicy IPhttp%3A%2F%2Fwww.expresspharmaonline.com%2F20080531%2Fmanagement01.shtmlIndia\'s nasacent patent regime is under the scanner and the industry is grappling with questions like - What is the long term solution to balance patent protection with patient needs, in developing countries like India and especially with life threatening conditions like India and especially with life threatening conditions like cancer and AIDS? What is the situation in other countries on such issues?Dr Gopakumar Nair, Dilip G Shah, Tapan Ray, Dr Ajit Dangi, Priyank GuptaArticle28-May-2008Express Pharmahttp%3A%2F%2Fwww.expresspharmaonline.com%2F20090315%2Fmarket01.shtmlIt is unfair to blame the MNCs for everything. The MNCs themselves are the most frequent targets of USFDA. Dr Gopakumar G Nair,Dr Ajit Dangi,Dr VenkateswarluArticle15-Mar-2009Express Pharmahttp://www.gnaipr.com/Acts/Form_No_1_._44_-_letter_for_its__amendment_16-3-2009.pdfIn the recent controversy on Marketing Approval the entry Patent Status in Form No. 44 came up for discussion rather prominently. Shri Dedashish Panda Article07-Apr-2009IDMA BULLETINhttp://www.gnaipr.com/Articles/Blocked in Transit.pdfAs aggressive IP enforcement continues at the hands of EU ports should goods in transit be protected when they are without a doubt intended for markets where their use is legitimate.D G Shah,Dr. Gopakumar NairNews10-Apr-2009Express Pharmahttp%3A%2F%2Fwww.gnaipr.com%2FArticles%2FReady+for+round+2.pdfLegally speaking a patent is an exclusionary right given by the government or the authorised authority to its inventor for a particular duration in respect of his invention. Dr Gopakumar G Nair,Dr M Venkateswarlu,Tapan Ray,A S Krishna,Ranga Iyer,A S KrishnaArticle16-May-2009Express Pharmahttp://www.gnaipr.com/Articles/Mumbai - Presentation to Secretary - DoP 21.07.09.pdfReproduced with due permission from Mr. D G Shah and IDMA.News21-Jul-2009IDMAhttp%3A%2F%2Fwww.gnaipr.com%2FArticles%2FWPTO.pdfAccording to a recent mass media report Fu Shuangjian who is currently deputy chief of Administration Bureau of Chinese Industry and Commerce paid a visit to Taiwan on June 15 2009 during which he gave a comprehensive presentation and outline on the latest situations and developments of Trademark applications and examinations in China.Mr Hung-Pang Bian Article21-Aug-2009World Patent & Trademark Law Officehttp://www.gnaipr.com/Articles/albarellosasociados.we...ber%20-%20November%202009.pdfThe National Federal Court of Appeals issued a very interesting sentence in which develops very important concepts as the trademark the registration and their reaches among many others.Claudio Marcelo AlbarellosNews4-Oct-2009ALBARELLOS | ASOCIADOShttp://www.gnaipr.com/Articles/retrospective200903.pdfAs per TRIPS provision under Section 255 cross border measures really do not include patents and in transit materials because a majority of issues of counterfeit are related to quality and misbranding wrong branding informs Dr Gopakumar Nair Patent Attorney and CEO Gopakumar Nair Associates.Dr Gopakumar Nair ,D G ShahNews30-Nov-2009Express Pharmahttp://www.gnaipr.com/Articles/Genesis of Pre-grant Oppositions & its current status.pdfThe Patents Act 1970 as amended in 2005 with active participation from the lawmakers in the floor of the House introduced the provision for Pregrant Opposition for the first time in India. Dr Gopakumar G NairNews10-Dec-2009Pharmabizhttp://www.gnaipr.com/Articles/Third World Trade Organisation.pdfFor someone who calls himself a man of science Yusuf K. Hamied has a patent dis like for intellectual property rights. Yusuf K. Hamied News8-Jan-2010FORBES INDIAhttp://www.gnaipr.com/Articles/India asks firms to provide data on working of patents.pdfIndia has asked all patentees and licensees to provide information on the working of patents in the country before March 31st 2010. By Anju GhangurdeNews20-Jan-2010Scrip World Pharmaceutical News